• Underlying EBITDA guidance upgraded to ~$2.6 million, a 30% increase
• Margin expansion to ~16.3% driven by operational performance and cost efficiencies
• Revenue guidance refined to ~$16.0 million due to timing of revenue recognition

Resonance Health Limited (ASX: RHT) has upgraded its underlying EBITDA guidance for the financial year ending 30 June 2026 (FY26) to approximately $2.6 million, representing a 30% increase on previous guidance of $2.0 million. This upgrade is driven by continued strong operational performance, improved operating leverage, and margin expansion across the business. While FY26 revenue is now expected to be approximately $16.0 million, slightly below previous guidance of $17.0 million, this primarily reflects timing of revenue recognition associated with a major clinical trial agreement. The contracted revenue for this clinical trial agreement remains at approximately $13.8 million, with a greater proportion now expected to be recognised in FY27. The upgraded guidance implies an FY26 underlying EBITDA margin of approximately 16.3%, ahead of previous expectations. This reflects the benefits of Resonance's strategy to focus on clinical trial services, including the provision of Software-as-Medical Devices (SaMD), and other higher-margin opportunities, while maintaining disciplined cost control. The result represents a meaningful milestone in the Company's medium-term objective of scaling revenue toward approximately $30 million and achieving an underlying EBITDA margin of approximately 25%.

FY26 underlying EBITDA expected to be approximately $2.6 million, a 30% increase on previous guidance of $2.0 million. FY26 revenue expected to be approximately $16.0 million, slightly below previous guidance of $17.0 million.

Resonance remains well positioned to deliver sustained growth, supported by a diversified business model, strong contracted revenue base, continued expansion opportunities, growing contribution from higher-margin products and services, and ongoing investment in automation and AI-driven technologies to enhance scalability. The Company continues to target underlying EBITDA margin expansion over the medium-term as operating leverage increases and the business scales.